A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Conditions
Dravet Syndrome
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UCSF Benioff Children's Hospitals, San Francisco, California, United States
Contact: Principal Investigator (Adam Numis)Colorado Children's Hospital, Aurora, Colorado, United States
Nicklaus Children's Hospital, Miami, Florida, United States
Contact: Study coordinator (Dainelys Pena Rodriguez) · Dainelys.PenaRodriguez@nicklaushealth.org · 786-624-3547Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Contact: Principal Investigator (Linda Laux)Boston Children's Hospital, Boston, Massachusetts, United States
Mott Children's Hospital, Ann Arbor, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
Duke Children's Hospital & Health Center, Durham, North Carolina, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
Oregon Health and Science University (OSHU), Portland, Oregon, United States
Cook Children's Medical Center, Fort Worth, Texas, United States
Contact: Study coordinator (Dianna Grado, RN, CCRC) · Dianna.Grado@cookchildrens.org · (682) 885-2844Contact: Principal Investigator (Scott Perry)The Royal Children's Hospital, Melbourne, Australia
Contact: Study coordinator (Prof. Ingrid Scheffer)Contact: Study coordinator (Dr. Katherine Howell)Queen Elizabeth Hospital, Glasgow, United Kingdom
Great Ormond Street Hospital, London, United Kingdom
Study leads
Salvador Rico, M.D., Ph.D
Study Director
Encoded Therapeutics